Andres Poveda, MD, discusses the results of the phase 3 SOLO2 trial in advanced ovarian cancer.
Andres Poveda, MD, Initia Oncology, Hospital Quironsalud, in Valencia, Spain, discusses the results of the phase 3 SOLO2 trial in advanced ovarian cancer.
The results of the SOLO2 trial support the use of PARP inhibitors as maintenance therapy in patients with advanced platinum-sensitive relapsed ovarian cancer who harbor BRCA1/2 mutations, says Poveda. In the trial, olaparib (Lynparza) led to a clinically meaningful improvement in overall survival (OS) versus placebo in this patient population.
The median OS was 51.7 months with the PARP inhibitor versus 38.8 months with placebo (HR, 0.74; 95% CI, 0.54-1.00; P = .0537). At 5 years, 42.1% of women who received olaparib were alive versus 33.2% of those who received placebo. The SOLO2 trial is the first phase 3 trial to provide OS data on a maintenance PARP inhibitor, says Poveda.
Additionally, 22% of patients received olaparib for at least 5 years, reflecting the clinical benefit and tolerability of the agent.